

---

## Leidos Expands OnPAR Membership to Include the Epilepsy Foundation

FREDERICK, Md., [October 6, 2016] – Leidos welcomes the Epilepsy Foundation to OnPAR, the Online Partnership to Accelerate Research. OnPAR, originally launched by the Leidos Life Sciences team in March 2016, is a partnership with the National Institutes of Health (NIH) that offers a new funding paradigm with the goal of matching highly scored, unfunded applications with potential non-government organizations. The Epilepsy Foundation’s mission is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives. The Foundation’s vision is a world without epilepsy; ensuring that people with seizures live to their fullest potential.

OnPAR provides a second opportunity for promising, unfunded NIH research proposals. Through the OnPAR public-private partnership, high-quality research applications that were not originally funded by the NIH will be matched for potential funding with a participating organization member's specialized area of interest. “We welcome the Epilepsy Foundation to OnPAR,” says Martin Dueñas, Director, Health Research Management Practice, Leidos Life Sciences. “OnPAR seeks to revolutionize the scientific funding environment and accelerate discovery to improve lives for people impacted by epilepsy.”

Epilepsy Foundation’s national network is made up of nearly 50 local organizations charged with serving close to 40 states. During more than 40 years of service, the Epilepsy Foundation and its generous supporters have channeled more than \$52 million into epilepsy research. Through OnPAR, the Epilepsy Foundation network will review unfunded applications, primarily focusing on fellowships and new investigators who are addressing problems that are of high priority to those living with epilepsy.

“OnPAR presents a great opportunity to fund promising fellows and young investigators to sustain the pipeline of epilepsy researchers and support new ideas for epilepsy research,” says Brandy Fureman, PhD., Vice President of Research and New Therapies at the Epilepsy Foundation.

Any funding organization interested in becoming a member can find more information on the OnPAR website at <https://onpar.leidosweb.com>. We anticipate that both new partners and members will be joining soon. Please visit OnPAR frequently for further announcements and join us in our effort to accelerate research and find cures and treatments for the many diseases affecting our communities.

### **About Leidos**

Leidos is a global science and technology solutions leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 33,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported pro forma annual revenues of approximately \$10 billion for the fiscal year ended Jan. 1, 2016 after giving effect to the recently completed combination of Leidos with Lockheed Martin's Information Systems & Global Solutions business (IS&GS). For more information, visit [www.Leidos.com](http://www.Leidos.com).